
|Videos|June 11, 2015
Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma
Author(s)Catherine M. Diefenbach, MD
Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5




















